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Introduction 1 
The use of inkjet printing (IJP) technology is gaining considerable interest for additive manufacturing of 2 
pharmaceutical drug delivery systems (1, 2). Printing offers multiple advantages for manufacturing of drug 3 
products such as precise dosing, production of multi-dose regimens and ultimately personalized medicine, 4 
optimized for the treatment of the specific patient (3). When conducting IJP of pharmaceuticals, the active 5 
pharmaceutical ingredient (API) is either dissolved or suspended in an ink base and then precisely 6 
deposited on the substrate, i.e., a carrier, from a printer’s nozzle in a digitally controlled way (4).In spite of 7 
the evident benefits of IJP, production challenges exist in regard to using inkjet printing for manufacturing 8 
of personalized medicine.   Inkjet printing of pharmaceuticals is currently a low-output method, meaning 9 
that the number of dosage forms produced in IJP is limited. While it is easy to conduct API content analysis 10 
using well-established methods such as UV spectroscopy and HPLC analysis, these methods require the use 11 
of destructive sample preparation that is costly. Therefore, the API content analysis of the printed dosage 12 
forms should ideally be conducted using non-destructive, robust and fast methods (5). This is especially 13 
important in the future to realize on-demand and near the end-users pharmacoprinting of personalized 14 
medicine (6) or to integrate it in a continuous manufacturing setup (7, 8) according to the emerging 15 
regulatory framework (9). Recently, multiple methods have been described for non-destructive API content 16 
analysis in printed dosage forms. Vakili et al. used near-infrared chemical imaging for content analysis of IJP 17 
theophylline using copy paper as the model substrate (10). Researchers from the same group have used a 18 
colorimetric technique for content determination of IJP propranolol with colorant added, using edible rice 19 
paper and edible icing sheets as the substrates (11) and was also used for quantitative determination of IJP 20 
vitamin B2 doses on edible rice paper and copy paper (12). More recently, a handheld near-infrared 21 
spectrometer has been reported for API quantification on the IJP dosage forms, containing levothyroxine 22 
sodium and prednisolone. Edible icing sheets and solvent-casted films, containing cellulose derivatives, 23 
were used as the substrates (13). ATR-FTIR was used for quantifying loperamide and caffeine printed on 24 
poly-tetrafluoroethylene films (14).  Recently, our group used Raman spectroscopy for the quantification of 25 
IJP haloperidol on inorganic compacts and commercial paracetamol tablets (15). Raman spectroscopy has 26 
also been used for the assessment of polymorphism of prednisolone IJP onto polytetrafluoroethylene 27 
(PTFE) fiber glass films (16). In addition, confocal Raman mapping was conducted to describe drug 28 
distribution in the multi-layered films with three jet-dispensed model drugs (17). While the analytical 29 
techniques mentioned here have the potential to be used in a manufacturing-on-demand setting (such as 30 
in a community pharmacy), they also have drawbacks. For example, the colorimetric technique determines 31 
the content of the printed API indirectly by quantifying the coloring agent, added to the ink along the API. 32 
This could potentially lead to errors in estimating the actual API content due to, for example, degradation 33 
of the API, discoloration and/or migration of colorants. Measurements with spectroscopic techniques, such 34 
as near-infrared (NIR) and Raman spectroscopy, put certain demands on the morphology of the substrates, 35 
for instance, near-infrared chemical imaging requires the substrate to be completely flat in order to achieve 36 
accurate focusing of the diffusely reflected light (18). The handheld NIR method can in turn be prone to 37 
localized variation of the obtained spectra within the printed dosage form, e.g., if the substrate is porous 38 
and there is a variation in the absorption of the ink, or if the API crystallizes on the surface of the substrate, 39 
and therefore, different regions of the same printed area may give different results leading to errors in the 40 
correct determination of the drug content in the dosage form. Raman spectroscopy is also prone to 41 
variations in the material density of the substrate, e.g., when a highly porous vacuum-oven dried 42 
hypromellose was used as substrate, it was unsuitable for quantifying the drug content using spectroscopic 43 
methods (15). Besides that, measurements with NIR would be affected by residual solvents, in particular 44 
moisture from vapor sorption. It is evident from these examples that there is a need for gaining a better 45 
understanding about the analytical technique(s) in terms of its sensitivity and suitability to determine the 46 
drug content in a porous substrate.  47 
In this study we describe inkjet printing of three APIs on novel porous substrates prepared from 48 
hypromellose and the investigation of two spectroscopic techniques for the non-destructive and accurate 49 
determination of the inkjet printed drugs. Three model APIs, namely montelukast, haloperidol and 50 
propranolol in various doses were printed on the custom-developed substrates. The printed doses were 51 
analyzed using NIR spectroscopy and Raman spectroscopy and the resulting spectra were correlated to the 52 
API content measured by HPLC using Partial Least Squares (PLS) regression. The resulting models were 53 
compared in regards to their accuracy and prediction power.  54 
Materials and Methods 55 
Three model active pharmaceutical ingredients (APIs) were used in this study: haloperidol and propranolol 56 
hydrochloride were purchased from Sigma Aldrich (St Louis, MI, USA), and montelukast sodium was 57 
obtained from Matrix Laboratories (Hyderabad, India). Propylene glycol (PG) and lactic acid (LA) were 58 
obtained from Sigma Aldrich, ethanol (96 %) was supplied by Altia OY (Helsinki, Finland). Hypromellose 59 
(hydroxypropyl methylcellulose), HPMC, Metolose® 60SH-4000, was purchased from Shin-Etsu Chemical 60 
Co. (Tokyo, Japan), macrogol 4000, polyethylene glycol 4000, PEG4000, and polysorbate 20, Tween® 20, 61 
were purchased from Fluka Analytical (Seelze, Germany). Erythrosine (E127) was supplied by Merck 62 
(Darmstadt, Germany), blue food coloring liquid, containing brilliant blue (E133), was supplied by Dr. 63 
Oetker (Bielefeld, Germany).  64 
Preparation of substrates 65 
A single substrate (sample name S3) was produced as described in a recent paper (19). It was prepared by 66 
mixing 5 g HPMC with 0.5 g macrogol 4000, glycerol and polysorbate 20 and 2.1 g poloxamer 188. This 67 
mixture was added to purified water at 70°C under stirring. The total mass of the mixture was 100 g. After 68 
cooling the mixture to room temperature, it was cast into several silicone molds (10×28 cm2). Casting was 69 
done so that the approximate height of the liquid in the mold was 5 mm. The formulation in the casting 70 
molds was cooled to 5 ± 3 °C for 24h in order to allow complete hydration of the polymer. The samples 71 
were then freeze-dried using an Epsilon 1-4 LSCplus Pilot Scale Freeze Dryer (Martin Christ, Osterode am 72 
Harz, Germany). The samples were cooled to -30°C over 3 h, then held isothermally for 3 h after which the 73 
pressure was reduced and kept at 0.12 mbar while the temperature was increased to 0°C over 16.5 h 74 
during primary drying.  75 
Ink formulations 76 
Propranolol hydrochloride ink (50 mg/ml) was prepared by mixing PG:water in a ratio of 3:7. 10 drops of 77 
blue liquid fruit coloring were added through a cellulose pore filter (0.45 µm, Phenomenex, Torrance, CA, 78 
USA) to 100 ml of this mixture. 2.5 g propranolol hydrochloride was dissolved in this mixture in a 50.0 ml 79 
volumetric flask. The mixture was allowed to stand in an ultrasound bath for 30 min in order to ensure that 80 
API was dissolved.  81 
Montelukast sodium ink (200 mg/ml) was prepared by mixing PG:ethanol in a 3:7 ratio in a 100 ml 82 
volumetric flask. Two grains (approx. 1 mg) of erythrosine were added to the mixture. 10.0 g montelukast 83 
sodium was added to the mixture in a 50.0 ml volumetric flask. The mixture was put in an ultrasound bath 84 
for 2 h in order to ensure that montelukast sodium is dissolved completely.  85 
The haloperidol ink (160 mg/ml) was prepared by mixing LA:ethanol in a 16:84 ratio in a 50.0 ml volumetric 86 
flask. 1 drop of blue fruit coloring liquid and 1 grain of erythrosine was added resulting in slightly purple 87 
color. 4.0 g haloperidol was combined with the solvent mixture in a 25.0 ml volumetric flask. The mixture 88 
was put in the ultrasound bath for 30 min to dissolve haloperidol.  89 
Inkjet printing  90 
Inkjet printing was done on a PiXDRO LP50 piezoelectric inkjet printer (Roth & Rau, Eindhoven, 91 
Netherlands) mounted with a Spectra SL-128 AA print head with 128 nozzles (Fujifilm, Tokyo, Japan). The 92 
ink for printing was loaded into the ink container through a syringe equipped with a cellulose pore filter 93 
(0.45 µm, Phenomenex®). Propranolol ink was printed using a voltage of 90 V and a pulse ratio of 90 % with 94 
an ink pressure of -21.0 mbar. Montelukast ink was printed using a voltage of 120 V and a pulse ratio of 95 
85% with an ink pressure of -22 mbar. The haloperidol ink was printed with a voltage of 120 V and a pulse 96 
ratio of 90 % with a pressure of -23.9 mbar. All the inks were printed in 1 × 1 cm2 squares and 6-8 samples 97 
were printed for each dosing step. The number of layers printed and the dosage regimen for each API is 98 
described in Table I. Drop shape and size analysis on all the inks were done using Advanced Drop 99 
Calculation software (Meyer Burger Technologies, Eindhoven, Netherlands). 100 
Table I. Overview of printed samples on the different substrates.   101 
API Number of layers 
printed 
API content 
per step, mg 
Dose regimen, mg (calculated) 
Propranolol 
hydrochloride 
5-35 in steps of 5 0.6 0.6; 1.2; 1.8; 2.4; 3.0; 3.5; 4.1 
Montelukast 
sodium 
5-30 in steps of 5 2.1 2.1; 4.2; 6.3; 8.4; 10.5; 12.6 
Haloperidol 2-14 in steps of 2 0.6 0.6; 1.2; 1.8; 2.4; 3.0; 3.6; 4.2 
  102 
Dynamic viscosity and surface tension  103 
The viscosity of the API-containing inks was measured on an AR-G2 rheometer (TA Instruments, New 104 
Castle, DE, USA), equipped with a cone-plate geometry (Ø = 60 mm). The cone angle was 0.9811°. 1.05 ml 105 
of each ink solution was applied on the plate, thermostated to 25 °C, and subjected to a stationary shear 106 
stress ramp from 10 to 1000 s-1. The average of three measurements of the viscosity at 10, 100 and 1000 s-1 107 
was calculated and used to obtain the viscosity value of the ink by using Rheology Advantage software 108 
v5.7.2 (TA Instruments).  109 
The surface tension of the inks was measured with a DSA100 Drop Shape Analyzer (KRÜSS GmbH, 110 
Hamburg, Germany). The data were analyzed using Drop Shape Analysis 1.90.0.22 software (KRÜSS).  111 
Microscopy 112 
Visible light microscopy was conducted on a DM LM microscopy (Leica Microsystems GmbH, Wetzlar, 113 
Germany) equipped with an Evolution MP Camera (Media Cybernetics, Rockville, MD, USA) controlled by 114 
Image-Pro Insight software v 8.0 (Media Cybernetics). The microscope was operated in both reflected-light 115 
mode and polarized-light mode using a 10X objective. The surface and cross-sections of the printed 116 
samples were imaged in reflected-light mode, taking multiple exposures, each focusing on a different part 117 
of the sample and the resulting images were stacked in Adobe Photoshop CC 2018 v 19.0.1 (Adobe Systems 118 
Inc, San Jose, CA, USA), using the Auto-Blend Layers Function.  119 
High-performance liquid chromatography (HPLC) 120 
API quantification was performed on an Infinity 1260 HPLC system (Agilent Technologies, Santa Clara, CA, 121 
USA) using a C18 column (5 µm, 150 mm × 4.6 mm). The HPLC system was controlled by Infinity 1260 122 
software (Agilent Technologies). The mobile phase for analysis of propranolol consisted of 0.067 mM 123 
phosphate buffer (pH 3) and acetonitrile in a 60:40 ratio. For montelukast, the mobile phase was 1 mM 124 
acetate buffer (pH 5.9):acetonitrile in a 10:90 ratio . Haloperidol mobile phase consisted of 50 mM 125 
phosphate buffer (pH 2.5):acetonitrile in a 75:25 ratio. Standard curves were done for all APIs and linearity 126 
was observed (R2 = 0.998-0.999).  127 
Porosity and internal structure of the samples  128 
The porosity of the substrates was assessed using a custom-developed oil absorption method  (20) and  X-129 
ray computed microtomography (µCT). Samples of approximately 8 by 10 mm were cut out using a scalpel. 130 
The length, width and height of the samples were measured using a caliper (Mitutoyo Corporation, 131 
Kawasaki, Japan) and the mass was measured. The samples were then placed in paraffin oil (ρ = 0.862) in a 132 
desiccator at a pressure of 40 mPa for 24 hours. Then the samples were removed and excess oil was wiped 133 
off using a tissue. The samples were then weighed and the porosity, 𝛷, was calculated according to Eq. 1. 134 
𝛷 =
(𝑀𝑜−𝑀𝑠)/𝜌𝑜
𝑉𝑠
     Eq. 1 135 
Vs is the volume of the sample, Mo is the sample weight after oil absorption, Ms is the sample weight before 136 
oil absorption, ρo is the density of the oil.  137 
X-ray computed microtomography (µCT) analysis 138 
Samples of approximately 5 by 5 mm were cut and analyzed using a SkyScan 1172 µCT scanner (Bruker 139 
Corporation, Antwerp, Belgium). The samples were imaged at an isotropic voxel resolution of 5 µm. the 3D 140 
imaging was done by rotating the object through 180° in steps of 0.4°, recording the projection images 141 
using a cone beam configuration. 10 images were averaged for each position. A total of 1034 cross-section 142 
images per sample were generated with each sample requiring an acquisition time of about 1.2 h.  143 
Spectroscopic analysis of samples 144 
NIR spectroscopy of the surface of the dosage forms was conducted on a BOMEM MB-160 spectrometer 145 
(ABB, Zürich, Switzerland), controlled by Horizon MB software version 3.2.5.2 (ABB). 32 scans were 146 
obtained for each spectrum covering the range from 4000 to 12000 cm-1 and using a resolution of 8 cm-1. A 147 
spectralon reference standard (LabSphere Inc, North Sutton, NH, USA) was used to obtain a reference 148 
measurement before analyzing the samples. The samples were placed with each printed square centered 149 
on top of the analysis window.  150 
Near-infrared transmission (tNIR) spectroscopy was conducted on the BOMEM MB-160 equipped with a 151 
tablet sampler (Tablet Samplir, ABB). The sampler has 4 signal enhancement levels, depending on the 152 
opaqueness of the samples. The level was kept at 1 (lowest) throughout the measurements. 64 scans were 153 
obtained for each spectrum covering 5800 to 12000 cm-1 at a resolution of 8 cm-1. A transmission 154 
spectralon was used to obtain the reference measurement. The spectralon was kept in place while 155 
measuring the samples in order to decrease signal intensity and avoid oversaturating the detector.  156 
Raman spectroscopy in a backscattering setup was done on a Kaiser RXN1 Microprobe (Kaiser Optical 157 
Systems, Ann Arbor, MI, USA) with a PhaT-probe (Kaiser Optical Systems), controlled by HoloGRAMS 158 
software v 4.1. The laser wavelength used was 785 nm and the Raman shift from 150 to 1900 cm-1 was 159 
measured, each spectrum comprising 5801 data points. The laser spot size was 6 mm on the center of the 160 
printed samples and 6 exposures of 10 s each were averaged for each sample, giving a total exposure time 161 
of 60 s. A transmission setup was used as described earlier (21). The excitation fiber was placed directly 162 
beneath the sample and the Raman scattered light was collected by the PhaT-probe. The power of the laser 163 
was 200 mW at the output of the fiber. 6 exposures of 5 s each were averaged, giving a total exposure time 164 
of 30 s.   165 
Multivariate data analysis  166 
Spectral data (NIR and Raman) were analyzed using MatLab R2015a (Mathworks, Natick, MA, USA) and PLS 167 
Toolbox 8.0.1 (Eigenvector Research Inc, Manson, WA, USA). All the data were subjected to preprocessing 168 
in the form of Standard Normal Variate (SNV) transformation followed by Savitzky-Golay smoothing. 169 
Different window sizes were used, but all data were fitted to a 2nd order polynomial of which the 2nd 170 
derivative was taken. The regions in the spectra with the most contribution from the API were selected. 171 
After preprocessing and spectral selection, the data were modeled using Partial Least Squares (PLS) 172 
regression. The samples were randomly split into a calibration and validation set, the calibration set 173 
containing 2/3 of the samples and the validation set 1/3. Cross-validation was done using venetian blinds 174 
with 6 splits and 1 sample per blind.  175 
Results and Discussion  176 
Ink formulation and substrate preparation 177 
In this study, three different APIs, propranolol hydrochloride (propranolol), montelukast sodium 178 
(montelukast) and haloperidol were inkjet-printed on the porous sponge-like HPMC substrate. The 179 
substrate was developed as previously reported by our group to possess good absorption properties for the 180 
ink and good mechanical properties, i.e., to be flexible but at the same time, mechanically strong (22). The 181 
substrate was prepared from high-molecular weight hypromellose, containing various excipients: glycerol 182 
and macrogol 4000 were added as plasticizers, whereas polysorbate 20 was used as a surfactant, foaming 183 
agent and plasticizer. The resulting substrate was porous and the morphology of the surface pores 184 
reflected the shape of sublimated ice crystals. It is well-known that the shape and size of the formed ice 185 
crystals within the sample during freeze drying cycle would affect the microstructure and surface 186 
topography of the dried sample (23).  187 
The formulation of haloperidol- (15) and propranolol-containing (22) inks were done according to 188 
previously published work. The montelukast ink was formulated based on the solubility of the API in 189 
ethanol, and then modified so that the rheological and surface tension characteristics of the ink would be 190 
suitable for printing. In order to maximize the possible printed dose, the printable solvent system with a 191 
high concentration of the drug in it was selected, i.e., 200 mg/ml of montelukast in 3:7 PG:Ethanol ratio.  192 
The viscosity and surface tension of the drug-containing inks were all within the printable range (Table II).  193 
Table II. Surface tension and dynamic viscosity of the printed API-containing inks.  194 
Ink Surface Tension, mN/m Viscosity, mPa·s 
Propranolol 47.95 ± 0.12 3.11 ± 0.02 
Montelukast 27.81 ± 0.15 10.95 ± 0.87 
Haloperidol 28.34 ± 0.01 3.87 ± 0.05 
 195 
The use of porous substrates made of water-soluble polymer (HPMC) enables printing of multiple layers of 196 
the ink on the dosage forms without the risk of smearing of the ink during subsequent handling and 197 
thereby uncontrolled loss of the API. Indeed, the ink could absorb into the pores of the substrate. The 198 
choice of HPMC as the polymer was based on it being water soluble, pharmaceutically approved and being 199 
compatible with and APIs and the most common ink solvents, used for dissolving/suspending the APIs. It is 200 
known that HPMC is slightly soluble by ethanol. However, it was expected that the ethanol-based ink, 201 
jetted in picoliters during IJP, would rather absorb into the porous substrate than dissolve it. In contrast, it 202 
was expected that printing a water-based ink would dissolve the surface of the substrate. The substrates 203 
could easily be handled after printing and there was visually observed no smearing of the ink for any of the 204 
APIs (Fig. 1).  205 
The behavior of each ink in contact with the substrate was dependent on whether the ink was ethanol- or 206 
water-based (Fig. 2). The ethanol-based ink containing montelukast dissolved the surface of the substrate 207 
slightly when a high number of layers were printed, due to HPMC being soluble in ethanol to some extent 208 
(Fig. 2B). The haloperidol ink contained ethanol and also lactic acid, which has been shown to dissolve 209 
HPMC (24). However, the ink was only printed in a maximum of 14 layers which did not appear to change 210 
the surface significantly.A slight dissolution of the surface was observed when analyzed by microscopy (Fig 211 
2C). The water-based ink containing propranolol dissolved the surface of the substrate (HPMC 212 
dissolves/hydrates in water,) and a continuous polymer film (skin) was formed on the surface of the 213 
substrate, which was particularly evident when a higher number of layers was printed. The porous nature 214 
of the substrates enabled them to quickly absorb the ethanol-based inks during printing without 215 
signification dissolution of the surface of the substrate, highlighting the suitability of HPMC-based porous 216 
substrates for IJP of ethanol-based inks.  217 
Despite a slight surface dissolution of the substrate by montelukast inks with 30 layers printed (Fig 3B), the 218 
ethanol-based inks penetrated into the porous substrate as expected (Fig 3B and 3C). In general, the 219 
penetration depth of the ink was dependent on the localized variation of the density of the polymer within 220 
the substrate, i.e., the ink penetrated deeper into areas with larger  pores compared to areas with smaller 221 
pores as shown in Fig 3B. The penetration depth, evaluated by optical microscopy varied between 500-600 222 
µm for the montelukast ink, but it was difficult to assess the penetration depth for the haloperidol ink due 223 
to its weak color and the low amount of layers printed. The water-based propranolol ink concentrated at 224 
the surface of the substrate without penetration into pores of the carrier and propranolol was crystallized 225 
at the surface (Fig. 3D). 226 
Porosity and microstructure  227 
The new substrate was designed to be porous to facilitate the absorption of ink, and therefore the porosity 228 
of the carrier is a crucial parameter. Two different methods were investigated, a custom-developed oil 229 
absorption method and µCT for assessing the porosity of the substrate. While the oil absorption method 230 
only gives a single value of the porosity for a given type of substrate, µ-CT is able to visualize the internal 231 
structure of the samples, e.g., the pore size, their distribution and potential anisotropy of the material (25). 232 
The porosity of the freeze-dried substrate as measured by the oil absorption method was 0.92 ± 0.02 (n = 233 
3), showing that the freeze dried foams were highly porous as expected. The apparent porosity of the 234 
samples was lower for the µCT measurements, which gave values between 0.7-0.8 (results not shown). This 235 
is likely due to the different nature of the techniques with µCT being non-destructive and non-invasive 236 
compared to oil absorption, where interactions between the oil and the substrate take place. Despite the 237 
differences, both methods indicate that highly porous substrates were prepared using the freeze-drying 238 
method. The internal structure of the samples as measured by µCT revealed pores of varying size, 239 
presumably due to the variation in the size of the ice crystals during the freeze drying process. Two similarly 240 
prepared substrates had different apparent pore sizes (Fig. 4).  This difference could be due to internal 241 
variation within the freeze drier during the freeze drying process, e.g., in one part of the freeze drier the 242 
formation of ice crystals is faster, resulting in small ice crystals and thereby in small pores, while in another 243 
part the nucleation is slower resulting in larger crystals and thereby larger pores. It could also be due to the 244 
preparation method: variation in the distribution of the components within the formulation could affect 245 
the morphology of the product after freeze-drying. Better control of the freeze drying process parameters 246 
to affect the formation of ice crystals might alleviate this (23). Despite the observed differences in the 247 
porosity level and pore size, the samples appeared relatively homogenous. 248 
Drug content of the printed dosage forms 249 
In this study, the doses selected for printing of montelukast and haloperidol reflect clinical doses, i.e., 250 
haloperidol has a recommended daily dose between 0.5 and 4 mg for treatment of first-episode psychosis 251 
(26) and between 1 and 4 mg for treatment of schizophrenia (27). For montelukast  the range of clinically 252 
available doses is 4- 10 mg (28). For propranolol, the doses correspond to the daily uptake for treatment of 253 
infantile haemangioma (29), but higher doses are required in other indications (30). Despite not achieving 254 
the doses for adult treatment, they were printed in order to assess the effects of a water-based ink on the 255 
new substrates and the suitability for spectroscopic analysis.  256 
 The amount of the API deposited per layer is dependent on the concentration of API in the ink formulation, 257 
the droplet size and the area printed. For all three APIs, the content measured by HPLC correlated linearly 258 
with the amount of layers printed, indicating that the printing parameters did not vary significantly during 259 
the process (Figure 5). There was a slight deviation from the calculated content, but it was deemed 260 
acceptable.  261 
Spectral analysis  262 
Development of models  263 
The Raman and NIR spectra contain both physical and chemical information and must therefore be treated 264 
using preprocessing algorithms prior to modeling. In this study the focus was on the quantitative analysis of 265 
the API, therefore spectral variation from physical effects, such as density variation and pore size of the 266 
substrate, had to be addressed. This was done by systematic pretreatment of all the data.  The optimal 267 
window size, polynomial fitting and derivative applied is highly dependent on the nature of each analysis 268 
(31), therefore various approaches for the optimization of the Savitzky-Golay preprocessing were 269 
attempted and combinations of different preprocessing parameters were used as described in Table III.  270 
The substrate had a weak Raman scattering signal, likely a combination of two factors: (i) the primary 271 
ingredient of the substrate being HPMC which itself shows weak Raman scattering, and (ii) the low density 272 
of the substrate due to the sponge-like structure weakens the Raman signal. This makes the developed 273 
HPMC-based highly porous wafers good candidates for non-destructive analysis of printing APIs by Raman 274 
spectroscopy.  Montelukast proved to have a strong Raman scattering signal in both transmission and 275 
backscatter modes. Haloperidol had a weak signal in backscatter mode, but little to no signal in 276 
transmission mode. Analysis of the propranolol-containing samples was complicated by the presence of 277 
brilliant blue in the ink, which induced fluorescence, making Raman spectroscopy unsuitable for analysis of 278 
the propranolol containing samples. The montelukast samples, both measured in transmission and 279 
backscatter modes, contained a strong Raman contribution from montelukast in the region from 700-1700 280 
cm-1 . For haloperidol, the signal contribution was very low in transmission mode, however the signal was 281 
strong enough in backscatter mode to achieve a good signal useful for modeling.  282 
Raman spectroscopy has limitations in regard to quantitative analysis of inkjet printed pharmaceuticals. For 283 
instance, the presence of fluorescence is a disturbing factor, which can arise from the substrate, the API or 284 
the ink constituents. In addition, different compounds can possess varying Raman scatterering abilities that 285 
have to be taken into account when selection the ink-substrate combination. For example, if the substrate 286 
has a strong Raman contribution while the API has a weak contribution, determining the printed API 287 
content from the Raman spectrum can be challenging. Furthermore, when using a backscatter Raman 288 
setup, the penetration depth of the laser is of paramount importance; If the printed ink has penetrated 289 
deeper than the Raman laser, an incorrect API content may be predicted by the analysis.  290 
All the samples were analyzed by transmission NIR (tNIR). While all the APIs have strong and characteristic 291 
spectra when measured as pure powders, very little signal could be obtained when printed on the 292 
substrate. The obtained PLS models contained a large number of LVs and had poor prediction power. This 293 
technique was therefore discarded for quantitative analysis of the printed dosage forms. There can be 294 
multiple reasons for the failure of tNIR in analyzing the printed dosage forms. First of all, the used tNIR 295 
setup was optimized for tablet samples. Secondly, the used substrates are porous and require the 296 
reduction of the signal strength in order to not oversaturate the detector. This may cause the reduction in 297 
the spectral contribution from the APIs. Due to the failure of tNIR, where the entire bulk of the printed 298 
dosage form was analyzed, focus was then switched to surface NIR. Here, only the surface of the printed 299 
dosage forms was analyzed. All the APIs had strong signal contributions from the drug-printed samples 300 
compared to the blank substrates. Therefore, the resulting spectra contained contributions from both the 301 
substrate and the studied API (supplementary material). The PLS models for surface NIR showed excellent 302 
predictive performance for both montelukast and propranolol, while haloperidol showed worse predictive 303 
performance.  304 
The quality of the PLS models for the prediction of the API content was assessed by evaluating the number 305 
of latent variables (LVs), the relative contribution of each LV, the root-mean square error of cross-306 
validation/prediction (RMSECV and RMSEP, respectively) and the R2-value of cross-validation and 307 
prediction. The number of latent variables gives information on the complexity of the model and it should 308 
be evaluated against the RMSECV and RMSEP values that should be as small as possible.  The optimal 309 
selection of LVs gives usually a relatively low RMSECV and RMSEP and using a higher number of LVs does 310 
not improve predictive power of the model. The resulting selection of LVs should also ideally give a high R2 311 
value for both cross-validation and prediction, indicating that the predicted content gives a value close to 312 
the content measured by HPLC. The optimal selected models for all APIs and techniques are gathered in 313 
Table III.  314 
Table III. Summary of working PLS models for the different methods and APIs.  315 
API/substrate Method Variable 
selection, 
cm-1 
Preprocessing, 
(window size, 
polynomial, 
derivative)  
LVs RMSECV/RMSEP, 
mg 
R2 CV/ R2 
P 
Montelukast Transmission 
Raman 
150-1900 SNV, SG (81, 
2, 2) 
3 0.39/0.42 0.99/0.99 
 Surface 
Raman 
150-1900 SNV, SG 
(81,2,2) 
4 0.81/0.86 0.96/0.97 
 Surface NIR 3800-
6400 
SNV, SG (15, 
2, 2) 
4 0.34/0.39  0.99/0.99 
Haloperidol Surface 
Raman 
150-1900  SG (51, 2, 2) 2 0.15/0.15 0.98/0.99 
 Surface NIR 4100-
6600 
SNV, SG 
31,2,2 
5 0.24/0.20 0.96/0.97 
Propranolol Surface NIR 4100-
6300 
SNV, SG 31 2 2  5 0.21/0.23 0.98/0.99 
RMSECV: root mean square error of cross-validation, RMSEP: root mean square error of prediction, R2 CV: 316 
correlation coefficient of cross-validation sets, R2 P: correlation coefficient of validation set 317 
Table IV. Summary of the applicability of the spectroscopic methods for the non-destructive quantification 318 
of different APIs printed on porous substrates.  319 
 Montelukast 
 
Haloperidol 
 
Propranolol 
 
Transmission Raman Yes 
 
No 
 
No 
 
Surface Raman Yes Yes No 
Transmission NIR No No No 
Surface NIR Yes Yes Yes 
 320 
Comparing the different spectroscopic techniques and models studied does not yield an ideal method for 321 
all cases (Table IV). The appropriate analytical and modeling methods are API-dependent, and are affected 322 
by the resulting ink formulation and the substrate. Montelukast, being a strong Raman scatterer, gave good 323 
results when using the transmission setup, however poor fitting was achieved for the surface Raman setup. 324 
The good fitting for the transmission model can be ascribed to the transmission setup measuring the entire 325 
bulk of the dosage form, independent of penetration depth of the ink or variation in the density of the 326 
porous substrate. Surface Raman spectroscopy had a poorer performance, which can be due to the Raman 327 
laser not penetrating deep enough to get a linear correlation between the number of layers printed and the 328 
resulting spectra. Furthermore, both methods required a combination of SNV and Savitzky-Golay 329 
smoothing algorithm for preprocessing of the raw spectra. SNV, originally developed for standardization of 330 
NIR spectra, first transforms each spectrum to mean zero and unit standard deviation after which the 331 
Savitsky-Golay preprocessing smoothens the spectra and enhances shoulders and subtle differences in the 332 
spectra. While surface Raman yielded a poor model for montelukast, the surface NIR method yielded a 333 
good fitting, indicating that the penetration depth for surface NIR spectroscopy being high enough to 334 
measure the entire amount of the printed API. The best fitting for the predictive quantitative analysis of 335 
haloperidol was shown by the surface Raman method, compared to the NIR method. Interestingly, the best 336 
fit was achieved when using only Savitzky-Golay preprocessing without SNV transformation. The reason for 337 
this can be found in the raw spectra, which contained weak contributions from haloperidol and the 338 
substrate, plus a strong background contribution inherent to the instrument. Applying SNV means that the 339 
background contribution would be enhanced in the SG processed spectra, thereby weakening the 340 
prediction ability of the model (supplementary material). For propranolol, due to the addition of brilliant 341 
blue to the ink, it induced fluorescence with Raman spectroscopy, only NIR was usable, where a good 342 
predictability of the API content was achieved.  343 
Conclusion 344 
The use of spectroscopic techniques made it possible to fast and accurately determine the API content in 345 
dosage forms prepared by inkjet printing on porous substrates suitable for the printing process. Selecting a 346 
single optimal method for non-destructive determination of the API content in any printed sample is close 347 
to impossible as each technique has its advantages and drawbacks. That said, Raman in both transmission 348 
and reflectance mode and NIR spectroscopy in surface mode could be used in combination, complementing 349 
each other. However, in specific cases when one method fails for a given API (e.g. Raman spectroscopy due 350 
to fluorescence), another technique (NIR spectroscopy) could be used alone for assessing the API content.  351 
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